Communiqués Aerovate Therapeutics, Inc.

Actions

AVTE

US0080641071

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,66 ^USD	-0,60%		+6,41%	-92,66%

18/06	Les plus fortes baisses du jour	MT
18/06	AEROVATE THERAPEUTICS, INC. : Guggenheim neutre sur le dossier	ZM

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC	21/06	AQ
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	17/06	AQ
Aerovate Therapeutics : June 2024 Corporate Presentation	01/06	PU
Aerovate Therapeutics : May 2024 Corporate Presentation	21/05	PU
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference	21/05	AQ
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights	13/05	AQ
Aerovate Therapeutics : May 2024 Corporate Presentation	02/05	PU
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	27/03	AQ
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights	25/03	AQ
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair	06/03	AQ
Aerovate Therapeutics : March 2024 Corporate Presentation	01/03	PU
Aerovate Therapeutics : December 2023 Corporate Presentation	01/12	PU
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	20/11	AQ
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights	13/11	AQ
Aerovate Therapeutics : November 2023 Corporate Presentation	01/11	PU
Aerovate Therapeutics : October 2023 Corporate Presentation	02/10/23	PU
Aerovate Therapeutics : September 2023 Corporate Presentation	31/08/23	PU
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights	14/08/23	AQ
Aerovate Therapeutics : August 2023 Corporate Presentation	31/07/23	PU
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors	11/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Aerovate Therapeutics, Inc.

Actions

AVTE

US0080641071

Communiqués

Filtres